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Key questions
What is already known about this subject?
 ► There remains a lack of consensus on optimal right 
ventricular lead placement.
What does this study add?
 ► Periprocedural complication rates and long-term 
clinical outcomes for septal and apical right ventric-
ular lead placement are similar.
 ► Fluoroscopy-guided right ventricular septal lead 
placement does not consistently result in a narrow 
paced QRS duration.
 ► Patients in whom narrow paced QRS duration 
is achieved have a favourable long-term clinical 
outcome.
How might this impact on clinical practice?
 ► Reduction of QRS duration is crucial and should be 
prioritised when placing right ventricular leads.
 ► Pacing strategies for routine clinical practice that re-
sult in more consistent reduction of QRS should be 
the focus of future research in this field.
AbstrAct
Objectives Optimal right ventricular lead placement 
remains controversial. Large studies investigating the 
safety and long-term prognosis of apical and septal right 
ventricular lead placement have been lacking.
Methods Consecutive patients undergoing pacemaker 
insertion for high-degree atrioventricular block at 
Edinburgh Heart Centre were investigated. Periprocedural 
30-day complications were defined (infection/bleeding/
pneumothorax/tamponade/lead displacement). Long-term 
clinical outcomes were obtained from the General Register 
of Scotland and electronic medical records. The primary 
endpoint was a composite of all-cause mortality, new 
heart failure, hospitalisation for a major cardiovascular 
event, as per the CArdiac REsynchronization in Heart 
Failure trial. Secondary endpoints were all-cause mortality, 
new heart failure and their composite.
Results 820 patients were included, 204 (25%) paced 
from the septum and 616 (75%) from the apex. All 
baseline variables were similar with the exception of age 
(septal: 73.2±1.1 vs apical: 76.9±0.5 years, p<0.001). 
Procedure duration (58±23 vs 55±25 min, p=0.3), 
complication rates (18 (8.8) vs 46 (7.5)%, p=0.5) and 
postimplant QRS duration (152 (23) vs 154 (27) ms, p=0.4) 
were similar. After 1041 days (IQR 564), 278 patients met 
the primary endpoint, with no difference between the 
septal and apical groups in unadjusted (HR 0.86 (95% CIs 
0.64 to 1.15)) or multivariable analysis correcting for age, 
gender and comorbidity (HR 0.97 (95% CI 0.72 to 1.30)). 
Similarly, no differences were observed in the secondary 
endpoints.
Conclusions This large real-world cohort of patients 
undergoing right ventricular lead placement in the 
septum or apex demonstrated no difference in procedural 
complications nor long-term clinical outcomes. Both 
pacing strategies appear reasonable in routine practice.
IntROduCtIOn
Cardiac pacing devices are central to 
modern cardiology with over 500 000 devices 
implanted in the annually across Europe.1 
Higher degree atrioventricular block remains 
an important indication for pacing2 in order 
to mitigate against the risk of syncope, 
progressive heart failure and sudden cardiac 
death. However, there remains a lack of 
consensus on the optimal positioning of the 
right ventricular lead in terms of cardiac 
function and long-term clinical outcomes.3
Conventionally, right ventricular leads are 
placed at the apex, but increasing evidence 
suggests this strategy may have deleterious 
effects on cardiac function by producing 
an iatrogenic left bundle branch block 
(LBBB) pattern on the ECG and dyssynchro-
nous ventricular contraction.2 4 The LBBB 
ECG pattern is associated with worse clin-
ical outcomes in both diseased and normal 
hearts,5–8 with recent data suggesting that 
pacemaker-related LBBB is similarly disad-
vantageous. Indeed patients with severely 
impaired left ventricular function and high 
right ventricular apical pacing burdens 
(50%–100%) have an increased subsequent 
incidence of heart failure compared with 
patients with low burdens (0%–50%).9 This is 
thought to relate to the interventricular and 
intraventricular electrical and mechanical 
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Figure 1 Study flow chart, with exclusions. CRT, Cardiac Resynchronisation Therapy; ICD, Impantable Cardioverter 
Defibrillator; PPM, Permanent Pacemaker; RV, Right Ventricle.
dyssynchrony2 7 10 that occurs with apical pacing, which 
can lead to adverse remodelling,11 altered cardiac 
perfusion12 and impaired function.13 Even in patients 
with preserved left ventricular systolic function, there is 
evidence to suggest some reduction in function with both 
apical and septal pacing.14
Alternative pacing strategies achieving more physiolog-
ical depolarisation might improve ventricular synchrony 
and protect against these detrimental effects. These 
include minimal ventricular pacing algorithms, upgrade 
to cardiac resynchronisation therapy and His-bundle 
pacing.15 However, the most widely used strategy is pacing 
of the right ventricular septum and outflow tract.2 7 The 
rationale is that pacing from these septal sites might allow 
recruitment of the intrinsic cardiac conduction system 
that lies in close proximity, thereby reducing QRS dura-
tion and subsequent ventricular dyssynchrony.15 Septal 
pacing is also attractive because it is less technically chal-
lenging than other strategies such as cardiac resynchroni-
sation therapy and His-bundle pacing.14 15 Moreover, it is 
generally accepted that septal lead placement avoids the 
perioperative risk of cardiac perforation and tamponade 
compared with apical lead placement. However, concerns 
have been raised about the risks of lead displacement and 
the ability of this approach to reliably recruit the intrinsic 
conduction system.15 16
In the present study, we aimed to investigate the proce-
dural safety and long-term clinical outcomes of a large 
real-world cohort of patients with higher degree atrio-
ventricular block non-selectively assigned to pacing oper-
ators with preference for either septal or apical right 
ventricular pacing strategies.
MetHOds
Consecutive patients undergoing pacemaker device 
implantation from 16 April 2010 to 29 September 2016 
at the Edinburgh Heart Centre were included in the 
study. Over the study period, there were five operators 
with two favouring septal right ventricular lead place-
ment and three favouring apical lead placement. All 
septal lead placements were achieved with active fixa-
tion leads using stylets fashioned by the operators to 
facilitate septal positioning. No preshaped stylets or 
steerable sheaths were used. The final septal positions 
were confirmed using fluoroscopy (posteroarterior 
(PA) and left anterior oblique (LAO) 40 projections) 
and assessment of the current of injury. In comparison, 
most apical lead placements were achieved with active 
fixation leads (n=483, 78.4%) using PA and right ante-
rior oblique fluoroscopy projections. Patients listed for 
permanent pacemakers were placed in a central pool 
and then non-selectively allocated to 1 of 6 weekly lists at 
our institution. Inclusion criteria were defined to select 
patients undergoing new right ventricular lead implan-
tation (either new device implants or ventricular lead 
repositioning) for high-degree atrioventricular block 
(second/Mobitz type 2 or third-degree atrioventricular 
block). Exclusion criteria were pacemaker implanta-
tion for isolated sick sinus syndrome or other condi-
tions associated with low ventricular pacing burdens 
and patients undergoing cardiac defibrillator or resyn-
chronisation therapy system implantation. Patients in 
sinus rhythm undergoing single-lead device implanta-
tion were excluded in an attempt to exclude frail and 
unstable patients with an inherently poor prognosis 
who may be more likely to have an apical lead placed 
(figure 1). Clinical audit approval for this study was 
provided by the Edinburgh Heart Centre.
data collection
Data were collected using a prespecified collection 
protocol and standardised case report form from elec-
tronic medical records. Baseline clinical and procedural 
data were collected by a single observer (KW) blinded to 
clinical outcomes. Data on preimplantation medication 
and comorbid conditions were recorded including atrial 
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Table 1 Demographic comparison of apical and septal 





Age (year) 77±11 73±15 <0.001
Gender (♂) 382 (62) 125 (61) >0.9
Urgency (urgent) 396 (65) 136 (67) 0.7
Dual/single chamber (dual) 565 (92) 193 (95) 0.2
Comorbidities 
  Atrial arrhythmia 152 (25) 41 (21) 0.3
  Heart failure 55 (9) 17 (9) >0.9
  Renal failure 87 (14) 26 (13) 0.8
  Liver failure 0 0
  Metastatic cancer 7 (1) 0 (0) 0.3
  Stroke 86 (14) 22 (11) 0.3
  Diabetes mellitus 122 (20) 37 (19) 0.8
  Hypertension 416 (68) 123 (62) 0.1
  Ischaemic heart disease 162 (27) 58 (29) 0.5
  CABG 37 (6) 19 (10) 0.1
  Valvular heart disease 172 (28) 62 (31) 0.5
  Valve surgery 52 (9) 22 (11) 0.3
Haematology/biochemistry 
  Haemoglobin 128±19 128±19 >0.9
  Creatinine 98±55 99±77 0.7
  Sodium 138±4 138±4 0.2
Medications 
  Diuretic 205 (34) 61 (31) 0.5
  ACEI/ARB 270 (44) 78 (39) 0.2
  Beta-blocker 80 (13) 27 (14) 0.9
  Digoxin 4 (1) 0 (0) 0.6
  Ca-channel blocker 103 (17) 30 (15) 0.7
  Amiodarone 9 (2) 4 (2) 0.8
ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin 
II receptor blocker; CABG, coronary artery bypass grafting; eGFR, 
estimated glomerular filtration rate.
Table 2 Thirty-day complication rates between apical and 
septal cohorts (n (%))







Bleeding/haematoma 8 (1) 6 (3) 0.1
Pneumothorax 16 (2) 5 (2) >0.9
Lead displacement 6 (1) 3 (2) 0.6
Infection 9 (2) 3 (2) >0.9
Cardiac tamponade 0 (0) 1 (1) 0.2
Other* 7 (1) 0 (0) 0.1
Composite periprocedural 
complication score
46 (8%) 18 (9%) 0.5
*Atrial lead dysfunction, right ventricular lead repositioning, right 
ventricular perforation without tamponade, wound dehiscence, 
pericarditis and subclavian vein thrombosis.
arrhythmias, congestive heart failure (symptomatic or 
echocardiographic ejection fraction <50%), chronic 
kidney disease (estimated glomerular filtration rate 
<60 mL/min/1.73 m2), liver failure, metastatic cancer, 
stroke or transient ischaemic attack, diabetes mellitus, 
hypertension (persistent blood pressure 140/90 mm 
Hg or higher), ischaemic heart disease (symptomatic 
of angina pectoris or imaging diagnosis), previous 
coronary arterial bypass grafting, valvular heart disease 
(murmur or echocardiographic diagnosis), previous 
valvular surgery and interventricular conduction delays 
(table 1). Procedural information was collected (KW) 
from electronic records and a national audit tool for 
cardiac procedures (St. Thomas’ Cardiac Audit Tool, 
TOMCAT) that routinely captures screening times, 
procedure times (patient time in theatre) and proce-
dural complications. Procedural complications were 
prespecified as bleeding/haematoma, pneumothorax, 
lead displacement, infection, cardiac tamponade, atrial 
lead dysfunction, right ventricular lead repositioning, 
right ventricular perforation without tamponade, 
wound dehiscence, pericarditis and subclavian vein 
thrombosis (table 2). A composite procedural compli-
cation score was calculated as the sum of each of these 
complications for patients undergoing apical and 
septal lead placement. The final right ventricular lead 
position was determined by the primary operator, using 
fluoroscopy and documented in the electronic medical 
records. Where available, postimplantation ECGs were 
assessed, and the duration of the paced QRS complexes 
recorded.
Clinical outcomes
Clinical outcome data were collected from the General 
Register of Scotland and electronic medical records, 
by an observer blinded to the baseline demographic 
and procedural data (NS). Our composite primary 
endpoint was prespecified and based on the CArdiac 
REsynchronization in Heart Failure trial17: all-cause 
mortality, congestive heart failure and hospitalisation 
for a major cardiovascular event. This was considered 
an appropriate primary endpoint as the mechanism by 
which non-apical pacing is proposed to improve clinical 
outcomes is similar to that of cardiac resynchronisation 
therapy by reducing QRS duration. The earliest event 
was used for the time-to-endpoint analysis. Prespecified 
secondary endpoints were all cause mortality, new-onset 
congestive heart failure and the composite of the two. 
A post hoc analysis examined a composite secondary 
endpoint of all-cause mortality, congestive heart failure, 
myocardial infarction, unstable angina, stroke, cardiac 
arrest and arrhythmia. Finally, an outcome analysis 
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statistical analysis
Statistical analysis was carried out in R (V.2.15.2, 
Vienna, Austria) and GraphPad Prism (V.7.0, Graphpad 
Software Inc., La Jolla, California, USA). Continuous 
variables were assessed using parametric and non-par-
ametric tests as appropriate, while categorical varia-
bles were compared using the Fisher’s exact test. Cox 
regression modelling was performed to define the HRs 
for all primary and secondary endpoints after adjusting 
for age, sex and comorbidities (chronic kidney disease, 
congestive heart failure, hypertension, diabetes mellitus 
and ischaemic heart disease). A post hoc Cox regres-
sion analysis with selected relevant clinical endpoints 
was also carried out. Finally, we performed a subgroup 
analysis to investigate the breadth of the paced QRS 
duration in patients with a septal lead (narrow complex 
paced QRS <130 ms vs broad complex paced QRS 
≥130 ms) and the effect of paced QRS duration on the 
primary endpoint.
Results
In total, 820 eligible patients were identified with 616 
(75%) in the apical and 204 (25%) in the septal right 
ventricular pacing groups. These two groups were well 
balanced for all baseline clinical variables including 
gender, comorbidities, medication and routine base-
line laboratory tests. The sole exception was age with 
patients having a septal lead being on average 3.7 years 
younger than those with apical leads (table 1).
There was no difference in procedure times (defined 
as time from skin preparation to skin closure) between 
apical and septal groups (58±23 vs 55±25 min, respec-
tively, p=0.34) or fluoroscopic screening times (defined 
as total screening time per procedure, 4.0±3.9 vs 
4.9±3.6 min, respectively, p=0.07). Pneumothorax, 
infection, bleeding and haematoma were the most 
frequent complications with no observed differences 
between the two groups in their incidence (table 2) or 
in the composite 30-day periprocedural complication 
score (7.5% (n=46) vs 8.8% (n=18), respectively, p=0.5, 
figure 2).
After a median of 1041 (IQR 564) days follow-up, 
278 patients met the primary endpoint (table 3). There 
was no difference in the primary endpoint between the 
septal and apical pacing groups in either unadjusted 
(HR 0.86, 95% CIs 0.64 to 1.15) or multivariable anal-
yses after correcting for age and gender (HR 1.02, 
95% CIs 0.76 to 1.36), and age, gender and presence 
of comorbidities (chronic kidney disease/congestive 
heart failure/hypertension/diabetes mellitus/isch-
aemic heart disease, HR 0.97, 95% CIs 0.72 to 1.30). 
Similarly, no differences between groups were observed 
for any of the prespecified or post hoc secondary 
endpoints (table 4, figure 3). In the post hoc anlaysis 
where pulmonary embolism and ruptured aortic aneu-
rysm were removed from the composite endpoint, 
there was no difference between septal or apical groups 
in either unadjusted (HR 0.91, 95% CIs 0.68 to 1.21) 
or multivariable analyses correcting for age and gender 
(HR 1.08, 95% CIs 0.81 to 1.45), and age, gender and 
comorbidity (HR 1.02, 95% CIs 0.76 to 1.38).
In a subgroup (n=343) where paced postimplant 
electrocardiograms were available, there were no 
differences in paced QRS duration between the septal 
and apical groups (mean 152±23 (n=87) ms vs 154±27 
(n=256) ms, respectively, p=0.4). Across the cohort as 
a whole, 16% of patients (n=14, 6.9% septal implants; 
n=40, 6.5% apical implants, p=0.9) demonstrated a 
narrow paced QRS (<130 ms) (excluding fusion and 
pseudofusion beats), while 84% (n=289) had a broad 
paced QRS (≥130 ms). Interestingly, patients in whom 
a narrow paced QRS (<130 ms) was achieved, irrespec-
tive of pacing site, demonstrated improved clinical 
outcomes compared with patients with a broad QRS 
(primary composite endpoint; 6% vs 17%, p=0.04). 
Kaplan-Meier curve analysis confirmed this finding 
with improved time-to-event outcomes in the narrow 
complex group (p=0.01; figure 4).
Figure 2 Mean procedure time and screening time (A, error 
bars indicate SD) and 30-day complication rates and (B) for 
septal (red) and apical (blue) patient groups.
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dIsCussIOn
In this large-scale retrospective analysis, where patients 
underwent right ventricular septal or apical pacing, we 
have demonstrated that right ventricular septal pacing 
is a safe alternative to the conventional apical approach 
with no increase in periprocedural complication rates 
or procedural times. However, septal pacing did not 
result in improved long-term clinical outcomes, perhaps 
because it did not consistently result in a narrow complex 
paced QRS. Both right ventricular septal and apical 
pacing are therefore reasonable strategies with further 
work required to develop simple approaches that more 
consistently reduce the paced duration of the QRS.
While not a prospective randomised trial, the present 
study provides analysis of real-world consecutive patient 
data at a tertiary referral centre, where patients are 
non-selectively assigned from a central pool to pacing 
lists performed by operators with a preference for either 
apical of septal lead placement. As a consequence, the 
right ventricular septal and apical pacing cohorts were 
well balanced across every baseline clinical characteris-
tics that were collected with the sole exception of age. 
Interestingly, the septal cohort was on average 3.7 years 
younger, perhaps reflecting the tendency to be less 
aggressive in striving for a septal pacing site in elderly 
patients. We therefore provide a robust and large real-
world dataset with which to investigate the procedural 
safety and long-term clinical outcomes of septal versus 
apical pacing.
Septal lead placement poses technical challenges,16–18 
raising concerns about lead displacement and the 
increased risk of complications with longer procedures. 
However, in this present study, we observed no difference 
in procedure duration, fluoroscopy times and periproce-
dural complication rates between the apical and septal 
cohorts. This was true both when considering each of 
the complications individually as well as the composite 
risk score, confirming septal lead placement as a readily 
feasible and safe alternative to apical pacing. Indeed, 
complication rates observed across our cohort as a whole 
were comprabale with other reported studies.19 20
Our second aim was to investigate whether septal pacing 
is associated with a favourable long-term prognosis. 
Despite a high event rate, no difference was observed 
between the right ventricular septal and apical pacing 
groups in the primary composite clinical endpoint, at 
median follow-up of 1041 days. Similarly, no difference 
was observed for any of the secondary clinical endpoints 
in multivariable analysis. What is the explanation for this 
result given the well-established literature outlining the 
adverse outcomes associated with LBBB and right ventric-
ular apical pacing? Selection bias has potential to favour 
apical lead placement given that operators may be more 
likely to attempt septal lead implantation in patients 
Table 3 Clinical outcomes in patients undergoing apical 








All-cause mortality 181 (29) 47 (23) 0.1
Unstable angina 8 (1) 5 (3) 0.3
Myocardial infarction 38 (6) 16 (8) 0.4
Pulmonary embolism 7 (1) 1 (1) 0.7
Cardiac arrest 6 (1) 1 (1) >0.9
Paroxysmal SVT/VT 41 (7) 4 (2) 0.01
Atrial fibrillation/flutter 43 (7) 14 (7) >0.9
Heart failure 38 (6) 10 (5) 0.6
Stroke 15 (2) 8 (4) 0.3
Ruptured AAA 6 (1) 1 (1) >0.9
Total 383 (62) 116 (57) 0.2
AAA, abdominal aortic aneurysm; SVT, supraventricular 
tachycardia; VT, ventricular tachycardia.
Table 4 Cox regression modelling; HRs for septal pacing for primary and secondary endpoints
Endpoint Model HR 95% CIs
Primary composite endpoint 1 (Unadjusted) 0.86 0.64 to 1.15
2 (Age, gender) 1.02 0.76 to 1.36
3 (Age, gender comorbidities*) 0.97 0.72 to 1.30
Secondary endpoints 
  All-cause mortality 3 (Age, gender comorbidities*) 0.92 0.66 to 1.28
  New-onset heart failure 3 (Age, gender comorbidities*) 0.69 0.24 to 1.67
  All-cause mortality/new onset heart failure† 3 (Age, gender comorbidities*) 0.90 0.65 to 1.23
  Modified composite endpoint‡ 1 (Unadjusted) 0.91 0.68 to 1.21
2 (Age, gender) 1.08 0.81 to 1.45
3 (Age, gender comorbidities*) 1.02 0.76 to 1.38
*Chronic kidney disease/congestive heart failure/hypertension/diabetes mellitus/ischaemic heart disease.
†All-cause mortality/new-onset heart failure.
‡As per CARE-HF, with pulmonary embolism and ruptured aortic aneurysm excluded.
CARE-HF, CArdiac REsynchronization in Heart Failure trial.
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with known left ventricular impairment. However, the 
high degree of similarity in comorbidity and medication 
between our patient groups suggests this was not the 
case. It is the analysis of the postimplantation ECGs that 
appears to provide the answer. In this large subgroup 
(n=343), no difference was observed in the paced QRS 
duration between the septal and apical pacing groups. 
Indeed, only 16% of the septal group achieved a narrow 
paced QRS (<130 ms), similar to the proportion in the 
apical cohort. Septal pacing therefore failed to reduce 
ventricular dyssynchrony compared with apical pacing, 
thereby explaining the similar outcomes. One potential 
explanation for this failure is that fluoroscopy is insuf-
ficient to guide accurate positioning of the pacing lead 
on to the septum. Recent studies have confirmed that 
only a minority of right ventricular leads are placed in 
the true septum using conventional fluoroscopic views 
and some have advocated the use of individualised LAO 
projection and echocardiography to confirm septal lead 
positioning.16 21 Alternatively, it may reflect variations 
in the anatomy of the His-Purkinje system. High septal 
right ventricular outflow tachycardia produces a broad 
complex QRS. It is perhaps unsurprising therefore that 
pacing in this region fails to achieve a narrow paced QRS. 
In comparison, fascicular tachycardia arising from the 
distal fascicles of the left bundle branch may produce 
a relatively narrow complex tachycardia. Pacing in this 
region might similarly result in a narrow apical paced 
QRS, potentially explaining the patients with a narrow 
paced QRS in the apical group.
Interestingly, the patients in whom a narrow QRS paced 
rhythm (<130 ms) was achieved, irrespective of pacing 
site, did demonstrate a lower risk of future adverse events 
compared with those with a broad QRS≥130 ms (0.05% 
vs 18.8%, respectively, p=0.01). This is consistent with the 
hypothesis that pacemaker-related LBBB is associated 
with an adverse prognosis and supports strategies that aim 
to achieve narrow complex pacing. Successful reduction 
in QRS duration can be achieved with cardiac resynchro-
nisation therapy, but this is time consuming. His bundle 
pacing is an alternative strategy with potential to produce 
the same QRS duration and mechanical function as atrial 
pacing.22 Technical challenges have also been reported 
with His bundle pacing including low success rates 
(65%), high complications rates, problems with ventric-
ular sensing and reduced generator lifespan due to 
higher pacing thresholds.23 However, Abdelrahman and 
colleagues demonstrated encouraging results in a recent 
observational cohort study of 765 consecutive patients.24 
While the average procedure and screening times were 
longer than for conventional pacing (70 and 10 mins vs 
55 and 7 mins, respectively, p<0.001) and there was an 
increased rate of ventricular lead revision, the authors 
demonstrated a signficiant reduction in QRS duration 
Figure 3 Kaplan-Meier plot for the prespecified primary 
endpoint (CARE-HF (A) and the secondary composite 
endpoint (all-cause mortality and new onset heart failure (B) 
in the septal (red) and apical (blue) cohorts. Median follow-up 
of 1000 days. CARE-HF, CArdiac REsynchronization in Heart 
Failure trial.
Figure 4 Kaplan-Meier plot for the primary composite 
endpoint in patient with a narrow paced QRS (<130 ms; 
green) versus broad paced QRS duration (≥130 ms; orange). 
Median follow-up of 1000 days.
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with His bundle pacing (128 (SD 27.7) ms vs 166 (21.8) 
ms, respectively) and a reduction in the composite clinical 
endpoint at 5 years. Improved strategies for septal pacing 
should also be explored, for example, by using steerable 
introducer sheaths, patient-tailored fluoroscopic projec-
tions and using intraoperative QRS duration and using 
QRS duration rather than fluoroscopic appearances to 
better guide lead placement on to the septum.
limitations
Echocardiography and pacing burden data were not 
available for analysis. This study was a retrospective anal-
ysis at a single centre and so is inherently limited by 
unforeseen counfounding factors and lack of randomi-
sation. However, the system of non-selective patient allo-
cation to pacing operators resulted in the balancing of 
all clinical variables examined with the exception of age. 
Similar balancing might therefore be expected among 
the unknown confounders.
COnClusIOn
In this large real-world observational analysis, proce-
dural safety and long-term clinical outcomes were similar 
between patients undergoing apical and septal right 
ventricular pacing. While septal pacing appears a safe 
and feasible strategy, further work is required to develop 
methods that can more consistently deliver narrow QRS 
right ventricular pacing.
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